News | December 06, 2023
Briefs: Shelter Pharma and GMM Pfaudler
GMM Pfaudler US completes acquisition of MixPro
GMM Pfaudler US completes acquisition of MixPro
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Lack of technology transfer stands out as a formidable barrier
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
